RBC raises target for Nanosonics stock from AUD 3.00 to AUD 3.75
Published on 10/07/2026 at 02:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Nanosonics stock (ISIN AU000000NAN9) is entering fiscal 2027 after RBC Capital Markets raised its price target from AUD 3.00 to AUD 3.75 on September 17, 2026. As The Motley Fool Australia reported, the revised target compared with a share price of AUD 2.88 at the time of the report.
RBC sees value in Trophon
The broker's case centers on Trophon, Nanosonics' established ultrasound probe disinfection business. Trophon EBIT increased from AUD 47.00 million in fiscal 2025 to AUD 50.00 million in fiscal 2026, while RBC forecast fiscal 2027 Trophon EBIT of AUD 54.00 million, according to The Motley Fool Australia.
The valuation argument is balanced by execution risk around CORIS, the company's second infection-prevention platform. Management plans its commercial launch in the first half of fiscal 2027, with initial revenue expected in the low single-digit millions.
Fiscal 2027 guidance sets the test
In its fiscal 2026 results briefing, Nanosonics reported AUD 203.90 million revenue, up 3 percent on a reported basis and 6 percent at constant currency. The same briefing put reported EBIT at AUD 16.00 million and constant-currency EBIT at AUD 21.60 million, up 21 percent from the prior year.
Management guided to fiscal 2027 constant-currency revenue of AUD 220 million to AUD 228 million, equal to 8 percent to 12 percent growth over fiscal 2026. Gross profit margin guidance is 74 percent to 76 percent, while operating expenses are expected at AUD 156 million to AUD 163 million, according to Yahoo Finance.
Buyback and AGM provide dates
Nanosonics also authorized an on-market buyback of up to AUD 40 million for fiscal 2027 after completing an AUD 20 million repurchase in fiscal 2026. The capital return supports the valuation case, but it coincides with higher investment in CORIS commercialization.
Simply Wall St identifies Nanosonics as ASX:NAN and lists its annual general meeting for November 4, 2026. The ASX listing gives Australian investors the direct reference for the company's fiscal 2027 execution, including CORIS launch progress and the revenue range.
Trading reference stays historical
The last Lang & Schwarz prior close was EUR 1.79 for October 5, 2026. The share's current investment debate therefore rests on the AUD 3.75 RBC target, the AUD 220 million to AUD 228 million fiscal 2027 revenue range and the timing of CORIS commercialization.
The further course of trading is shown by the continuously updated real-time quote of Nanosonics stock.
Nanosonics stock facts
- Company: Nanosonics Limited
- ISIN: AU000000NAN9
- Ticker: NAN
- Primary exchange: ASX
- Sector / Industry: Healthcare / Medical Instruments and Supplies
